Daiichi Sankyo
Last updated Jun 17, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
74%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Small Cell Lung Cancer
Highest priority development: FDA AP — ENHERTU (SUPPL)
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Daiichi Sankyo; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 74%
Active Signals
1
Investigate Priority
0
Opportunity Score
25
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 17, 2026Score 25Ifinatamab Deruxtecan Receives Priority Review for ES-SCLC in the U.S.
Oncology · Small Cell Lung Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — ENHERTU (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — ENHERTU (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — INQOVI (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — INQOVI (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Daiichi Sankyo right now?
- Which regulatory precedents should Daiichi Sankyo monitor in Oncology and Small Cell Lung Cancer?
- Which pipeline programs should Daiichi Sankyo prioritize for competitive review?
- What signals require immediate investigation for Daiichi Sankyo?
- Summarize the strategic implications of recent developments for Daiichi Sankyo.
- Where is the greatest uncertainty in Daiichi Sankyo's competitive positioning?